P. Nathan

发表

Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.

V. Goh, K. Miles, B. Ganeshan, 2011, Radiology.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

J. Utikal, D. Schadendorf, J. Becker, 2012, The New England journal of medicine.

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019, Journal of Clinical Oncology.

Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

H. Williams, Y. Takwoingi, J. Deeks, 2019, The Cochrane database of systematic reviews.

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma

P. Nathan, A. Hatswell, M. Bharmal, 2019, PharmacoEconomics - Open.

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors

A. Harris, D. Collins, A. Padhani, 2008 .

Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer.

P. Nathan, G. Stewart, S. Rossi, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Pregnancy and melanoma: a European‐wide survey to assess current management and a critical literature overview

G. Argenziano, C. Longo, S. Puig, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy

V. Goh, J. Larkin, M. Gore, 2013, British Journal of Cancer.

Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.

P. Nathan, R. Carvajal, Marlana Orloff, 2018 .

Uveal Melanoma UK National Guidelines.

B. Stedman, P. Szlosarek, P. Nathan, 2015, European journal of cancer.

NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus

D. Altman, V. Cerundolo, P. Nathan, 2015, International journal of cancer.

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

D. Schadendorf, K. Flaherty, P. Ascierto, 2020, Nature Medicine.

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

J. Larkin, A. Melcher, K. Harrington, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.

D. Schadendorf, L. Garraway, S. Jaeger, 2016 .

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity

V. Bataille, P. Nathan, H. Shaw, 2020, Journal for ImmunoTherapy of Cancer.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012 .

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients.

M. Gore, P. Nathan, R. Marais, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

T. Powles, J. Shamash, P. Nathan, 2012, European journal of cancer.

The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.

T. Powles, J. Shamash, P. Nathan, 2013, European journal of cancer.

Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib

D. Schadendorf, A. Ribas, D. Polsky, 2021 .

Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis

P. Nathan, H. Shaw, R. Mir, 2019, Melanoma research.

Immunosuppressive Agents and Their Role in Managing Immunotherapy Toxicities in Melanoma

P. Nathan, H. Shaw, R. Mir, 2017 .

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

A. Harris, D. Collins, A. Padhani, 2012, Clinical Cancer Research.

Circulating in ﬂ ammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

T. Spector, N. Segata, R. Fehrmann, 2022 .

Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer.

T. Eisen, H. Joensuu, P. Nathan, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild, D. Schadendorf, P. Ascierto, 2017, European journal of cancer.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

D. Collins, A. Padhani, D. Koh, 2015, The oncologist.

Metastatic disease from uveal melanoma: treatment options and future prospects

G. Schwartz, P. Nathan, R. Carvajal, 2016, British Journal of Ophthalmology.

Revised UK guidelines for the management of cutaneous melanoma 2010.

M. Gore, P. Nathan, P. Lorigan, 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Revised U.K. guidelines for the management of cutaneous melanoma 2010

P. Nathan, P. Lorigan, R. MacKie, 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Prediction of high naevus count in a healthy U.K. population to estimate melanoma risk

T. Spector, D. Glass, V. Bataille, 2016, The British journal of dermatology.

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

R. Motzer, D. Cella, H. Dastani, 2016, The Lancet. Oncology.

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.

D. Schadendorf, K. Flaherty, A. Ribas, 2021, The Lancet. Oncology.

Cutaneous Melanoma – A Review of Systemic Therapies

P. Nathan, Karla A. Lee, 2020, Acta dermato-venereologica.

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

D. Schadendorf, K. Flaherty, J. Kim, 2021, Clinical Cancer Research.

Epithelial ovarian cancer: a review of current management.

G. Rustin, P. Nathan, G. Rustin, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Vemurafenib in melanoma

P. Nathan, H. Shaw, 2013, Expert review of anticancer therapy.

What Is New in Melanoma Genetics and Treatment?

C. Longo, D. Glass, V. Bataille, 2016, Dermatology.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

J. Larkin, M. Gore, T. Powles, 2015, Molecular Cancer Therapeutics.

Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials.

M. Lens, V. Bataille, P. Nathan, 2007, Archives of surgery.

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.

J. Larkin, T. Choueiri, B. Rini, 2016 .

Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma

P. Nathan, Anup Vinayan, 2013, Therapeutic advances in medical oncology.

Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.

C. Porta, P. Nathan, V. Grünwald, 2016, European journal of cancer.

Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.

J. Larkin, P. Nathan, P. Lorigan, 2020, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

The biological treatment of renal-cell carcinoma and melanoma.

P. Nathan, T. Eisen, 2002, The Lancet. Oncology.

Trametinib in metastatic melanoma

P. Nathan, N. Chopra, 2015, Expert review of anticancer therapy.

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.

P. Nathan, J. King, 2014, Future oncology.

Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.

P. Nathan, D. McLaren, Janet E Brown, 2020, European urology focus.

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

T. Powles, P. Nathan, N. Vasudev, 2019, BMC Cancer.

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.

E. Frangou, M. Stockler, M. Parmar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

M. Gore, P. Nathan, R. Marais, 2011, British Journal of Cancer.

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

G. Schwartz, P. Nathan, R. Carvajal, 2015, BMC Cancer.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

J. Larkin, R. Plummer, P. Nathan, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

C. Porta, R. Motzer, T. Powles, 2019, The Lancet. Oncology.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

M. Gore, P. Nathan, P. Lorigan, 2014, The Lancet. Oncology.

Tests to assist in the staging of cutaneous melanoma: a generic protocol

H. Williams, Y. Takwoingi, J. Deeks, 2017 .

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

J. Larkin, P. Nathan, P. Lorigan, 2016 .

Melanoma—Part 2: management

P. Nathan, C. Thirlwell, 2008, BMJ : British Medical Journal.

Treatment of melanoma brain metastases

P. Nathan, C. Panje, S. Goldinger, 2016, Current opinion in oncology.

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.

M. Gore, P. Nathan, T. Eisen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

D. Berney, J. Shamash, C. Blank, 2011, European urology.

Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations.

W. Oyen, P. Nathan, P. Mulders, 2014, European urology.

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

Vicky Goh, V. Goh, P. Nathan, 2010, Cancer biology & therapy.

The place of VEGF inhibition in the current management of renal cell carcinoma

M. Gore, P. Nathan, M. Harries, 2006, British Journal of Cancer.

Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.

G. Linette, P. Ascierto, Xia Li, 2015 .

Unknown Primary Melanoma: Worldwide Survey on Clinical Management

R. Pampena, I. Zalaudek, G. Argenziano, 2017, Dermatology.

Review: Therapeutic opportunities in noncutaneous melanoma

P. Nathan, D. Wilkins, 2009, Therapeutic advances in medical oncology.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2010, British Journal of Cancer.

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020 .

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, Journal of Clinical Oncology.

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Michael Jeffers, Heikki Joensuu, Tim Eisen, 2012, The Lancet. Oncology.

A phase Ib trial of combretastatin A- 4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2005 .

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial

Martin O. Leach, David J. Collins, Anwar R. Padhani, 2009, European Radiology.

Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.

C. Watkins, P. Nathan, Kevin B. Kim, 2022, Journal of Clinical Oncology.

Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer

T. Powles, J. Shamash, I. Kayani, 2011, Clinical Cancer Research.

The role of CT scanning in the surveillance of testicular tumours.

P. Nathan, G. Rustin, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.

R. Motzer, E. Plimack, J. Sosman, 2016 .

Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.

T. Spector, V. Bataille, P. Nathan, 2020, European journal of cancer.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).

A R Padhani, A. Padhani, G. Rustin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound.

D. Nicol, T. Klatte, P. Nathan, 2019, European urology focus.

Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.

J. Larkin, P. Nathan, P. Lorigan, 2013 .

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

T. Powles, P. Nathan, N. Vasudev, 2019, BMC Cancer.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

G. Schwartz, P. Nathan, R. Carvajal, 2015, BMC Cancer.

Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.

P. Nathan, G. Bjarnason, C. Kollmannsberger, 2017 .

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

P. Nathan, H. Shaw, S. Howlett, 2023, Therapeutic advances in medical oncology.

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma

R. Plummer, M. Churchman, P. Nathan, 2013 .

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond

P. Nathan, S. Turajlic, B. Shum, 2023, Immuno-oncology technology.

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

M. Gore, P. Nathan, P. Lorigan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subacute CNS Demyelination after Treatment with Immune Checkpoint Inhibitors

P. Nathan, D. Ottaviani, H. Shaw, 2021 .

Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.

J. Patard, A. Ravaud, P. Nathan, 2017, European urology.

Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.

C. Porta, P. Nathan, C. Szczylik, 2014 .

7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

T. Eisen, H. Joensuu, P. Nathan, 2011 .

7105 Phase II trial of the oral multikinase inhibitor BAY 73–4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)

T. Eisen, H. Joensuu, P. Nathan, 2009 .

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.

P. Nathan, R. Carvajal, Takami Sato, 2017 .

First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.

J. Larkin, T. Powles, T. Choueiri, 2017 .

Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.

M. Gore, P. Hersey, A. Dalgleish, 2014 .

CT response assessment combining reduction in size and arterial enhancement correlates with time to progression in metastatic renal cancer patients treated with TKIs.

V. Goh, P. Nathan, Anup Vinayan, 2009, Journal of Clinical Oncology.

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies

A. Padhani, G. Rustin, P. Nathan, 2005 .

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

P. Ascierto, A. Arance, P. Queirolo, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

J. Larkin, M. Gore, T. Powles, 2015, Molecular Cancer Therapeutics.